Latest

Learn how lung cancer MRD ctDNA testing detects molecular residual disease, what positive and negative results mean, how it can precede recurrence on scans, and why treatment decisions still require clinical context.

Minimal Residual Disease ctDNA Test for Lung Cancer: Recurrence Monitoring, MRD, and Tumor DNA

Learn what MSI testing means in lung cancer, how MSI-H, MSS, dMMR, and pMMR results differ, how NGS, PCR, and IHC are used, and why this rare biomarker can matter for immunotherapy and hereditary evaluation.

MSI Test for Lung Cancer: Microsatellite Instability, Mismatch Repair, and Result Meaning

Learn how Napsin A IHC supports lung adenocarcinoma diagnosis, what positive granular cytoplasmic staining means, why negative results do not exclude lung cancer, and when other tumor origins must be considered.

Napsin A IHC Test for Lung Cancer: Adenocarcinoma Marker, Tumor Origin, and Positive...

Non-Small Cell Lung Cancer Biomarker Test: Driver Mutations, PD-L1, and Molecular Profile

Learn what an NSE blood test means in small cell lung cancer, why levels can be high, how hemolysis causes false elevations, and how serial NSE trends may support treatment and recurrence monitoring.

NSE Test for Lung Cancer: Small Cell Lung Cancer Marker, High Levels, and...

Understand NTRK fusion testing in lung cancer, including tumor-agnostic meaning, RNA NGS, pan-TRK IHC, positive results, negative-result limits, and next steps.

NTRK Fusion Test for Lung Cancer: Gene Fusion, Tumor-Agnostic Marker, and Molecular Meaning

Diagnostics

Home Diagnostics Page 2

Learn how exosome cancer tests analyze tumor RNA, proteins, DNA, and extracellular vesicles, what abnormal results may mean, and why most uses remain under research.

Exosome Cancer Test: Tumor RNA, Blood Biomarkers, and Diagnostic Research

Learn how FoundationOne Liquid CDx analyzes ctDNA for cancer mutations, how to read the genomic report, what companion-diagnostic findings mean, and why tissue testing may still be needed.

FoundationOne Liquid CDx Test: ctDNA, Cancer Genomics, Mutation Report, and Companion...

Learn how fragmentomics cancer blood tests analyze cell-free DNA length, ends, and genome-wide patterns, what classifier results mean, and why early-detection use still requires prospective validation.

Fragmentomics Cancer Blood Test: Cell-Free DNA Patterns and Early Detection Research

Learn how the Galleri multi-cancer early detection test uses cfDNA methylation, what Cancer Signal Detected and No Cancer Signal Detected mean, and what current trials show about accuracy and follow-up.

Galleri Test: Multi-Cancer Early Detection, Cancer Signal, and Result Meaning

Learn how Guardant360 Liquid CDx analyzes ctDNA for cancer mutations, what the current FDA-approved panel reports, how companion-diagnostic findings guide therapy, and why negative plasma results may need tissue confirmation.

Guardant360 Test: Liquid Biopsy, Cancer Mutations, ctDNA, and Genomic Profiling

Understand what a KRAS liquid biopsy measures, how ctDNA results are interpreted, and what KRAS mutations can mean in colorectal, lung, and pancreatic cancer.

KRAS Liquid Biopsy Test: Colon, Lung, Pancreatic Cancer, Mutation Status, and...

Learn how liquid biopsy resistance mutation tests detect ctDNA markers of cancer drug resistance, when testing is useful, how results are read, and why negative results may need tissue confirmation.

Liquid Biopsy Resistance Mutation Test: Cancer Drug Resistance Markers and Mutation...

Learn how liquid biopsy tests use circulating tumor DNA for blood-based cancer profiling, mutation detection, treatment selection, resistance testing, MRD monitoring, and result interpretation.

Liquid Biopsy Test: Circulating Tumor DNA, Blood-Based Tumor Testing, and Mutation...

Learn how the OncoBEAM ctDNA test uses BEAMing digital PCR for sensitive mutation detection, RAS testing in metastatic colorectal cancer, resistance monitoring, and blood-based result interpretation.

OncoBEAM Test: ctDNA Mutation Testing, Digital PCR, and Blood-Based Monitoring

Learn how the RaDaR ctDNA test uses personalized tumor mutations to detect MRD, monitor recurrence risk, and interpret positive or negative results.

RaDaR Test: ctDNA MRD, Cancer Monitoring, and Recurrence Detection

Understand how the Signatera ctDNA test detects personalized MRD, what positive and negative results mean, and how serial testing may signal cancer recurrence.

Signatera Test: ctDNA MRD, Cancer Recurrence, and Personalized Monitoring

Learn what the Tempus xF liquid biopsy tests, how xF differs from xF+, and how to interpret ctDNA mutations, negative results, MSI-H, and bTMB.

Tempus xF Test: Liquid Biopsy, Cancer Genomics, ctDNA, and Mutation Results

Learn how tumor-informed ctDNA tests personalize MRD monitoring, what positive and negative results mean, and how they compare with tumor-naive blood testing.

Tumor-Informed ctDNA Test: Personalized MRD Monitoring, Recurrence Detection, and Result Meaning

Tumor-Naive ctDNA Test: Blood-Based Cancer Monitoring Without Tumor Tissue

Learn how ALK testing helps classify anaplastic large cell lymphoma, what positive IHC or ALK rearrangement results mean, and when FISH or molecular confirmation is used.

ALK Test for Anaplastic Large Cell Lymphoma: Fusion Marker, Positive Result,...

Understand BCL2 rearrangement testing in follicular lymphoma, including IGH::BCL2, t(14;18), FISH results, negative tests, and how findings affect tumor classification.

BCL2 Rearrangement Test: Follicular Lymphoma, Rearrangement Status, and FISH Result

Learn how BCR-ABL1 quantitative PCR monitors CML, including International Scale percentages, MMR, MR4/MR4.5, milestone timing, rising results, and undetectable transcripts.

BCR-ABL1 Quantitative PCR Test: CML Monitoring, Molecular Response, and Transcript Level

Learn how BCR-ABL1 testing detects the Philadelphia chromosome in CML, how PCR, FISH, and karyotyping differ, and what positive or negative results mean.

BCR-ABL1 Test: Chronic Myeloid Leukemia, Philadelphia Chromosome, and Molecular Diagnosis

Learn how beta-2 microglobulin is used in multiple myeloma staging and prognosis, why kidney function changes the result, and how to interpret high levels.

Beta-2 Microglobulin Test for Myeloma: Staging, Prognosis, Tumor Burden, and Kidney...

Learn what a BTK mutation test means in CLL, how C481 and other variants cause BTK inhibitor resistance, and how positive or negative results are interpreted.

BTK Mutation Test: CLL Drug Resistance Marker and Mutation Meaning

123...92 Page 2 of 92